A patient on HIV treatment with tenofovir alafenamide (TAF) switches from tenofovir disoproxil fumarate (TDF). The key nephroprotective difference is due to:

• A TAF is a phosphoamidate prodrug that selectively delivers tenofovir intracellularly into lymphocytes at 90% lower plasma tenofovir levels, reducing renal tubular and bone toxicity that results from high plasma tenofovir exposure with TDF ✓
• B TAF is metabolised entirely by hepatic first-pass metabolism with zero renal elimination, eliminating nephrotoxicity
• C TAF is a CCR5 co-receptor antagonist added to tenofovir to reduce viral load and indirectly protect kidneys by reducing HIV-associated nephropathy
• D TAF achieves higher renal tubular concentrations than TDF, competitively blocking organic anion transporter-1 (OAT1) and thereby reducing cisplatin nephrotoxicity

Explanation

Tenofovir disoproxil fumarate (TDF) requires high plasma tenofovir levels to achieve intracellular activation in lymphocytes; these high circulating concentrations cause tubular uptake via OAT1/OAT3 transporters and accumulate in proximal tubular cells, impairing mitochondrial DNA polymerase gamma and causing tubular dysfunction (Fanconi syndrome), reduced eGFR, and bone mineral density loss. Tenofovir alafenamide (TAF) is a novel phosphonamidate prodrug 25 times more stable in plasma, preferentially cleaved intracellularly in lymphocytes by cathepsin A, achieving equivalent intracellular drug levels at 90% lower plasma exposure. This dramatically reduces renal and bone toxicity while maintaining virological efficacy.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.